Searchable abstracts of presentations at key conferences in endocrinology

Endocrine Abstracts

Published by BioScientifica
Previous issue | Volume 47 | Theranostics2016 | Next issue

4th Theranostics World Congress

4th Theranostics World Congress 2016

Spotlight on Prostate Cancer

Previous section
Spotlight on Neuroendocrine tumours
Table of contents
Next section
Innovative Theranostics

ea0047oc18 | Spotlight on Prostate Cancer

The Holy Grail: individualised dosimetry for radionuclide therapy

ea0047oc19 | Spotlight on Prostate Cancer

The history of PSMA and future directions

ea0047oc20 | Spotlight on Prostate Cancer

Evolving evidence of PSMA PET/CT

ea0047oc21 | Spotlight on Prostate Cancer

Should PSMA PET/CT replace conventional imaging?

ea0047oc22 | Spotlight on Prostate Cancer

PET/MRI: better AND worse than PET/CT for PSMA PET imaging

ea0047oc23 | Spotlight on Prostate Cancer

Imaging the expression of gastrin releasing peptide receptors in prostate cancer using Ga-68 labeled antagonists

ea0047oc24 | Spotlight on Prostate Cancer

How to get away with PET+MRI

ea0047oc25 | Spotlight on Prostate Cancer

Re-assessing gallium-67 as a therapeutic radionuclide

ea0047oc26 | Spotlight on Prostate Cancer

177Lu-DKFZ-PSMA-617 therapy in metastatic castration resistant prostate cancer: safety, efficacy and quality of life assessment

ea0047oc27 | Spotlight on Prostate Cancer

Initial experience with aggressive treatment of metastastic prostate cancer using 3 cycles of 7.4 GBq [177Lu]-PSMA every 4 weeks

ea0047oc28 | Spotlight on Prostate Cancer

Theranostic in early detection of recurring prostate cancer: 64CuCl2

ea0047oc29 | Spotlight on Prostate Cancer

A short history of transforming the diagnostic tracer PSMA-11 into the theranostic variant PSMA-617

ea0047oc30 | Spotlight on Prostate Cancer

Beyond wizardry: creating high level evidence for PSMA PET Imaging and Theranostics

ea0047oc31 | Spotlight on Prostate Cancer

First in-man study of 68Ga-THP-PSMA PET in patients with primary prostate cancer: initial results

ea0047oc32 | Spotlight on Prostate Cancer

Prostate specific membrane antigen targeted radioligand therapy of metastatic castration-resistant prostate cancer using Lu-177 PSMA-617: safety, efficacy and dosimetry in comparison with Lu-177 PSMA I&T

ea0047oc33 | Spotlight on Prostate Cancer

Molecular imaging with 64Cu-PSMA PET/CT in Theranostics of prostate cancer

ea0047oc34 | Spotlight on Prostate Cancer

Radiolabelling of DOTAMZOL with 68Ga and 44Sc for clinical application

Published by BioScientifica

Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2025 | Privacy policy | Cookie settings

BiosciAbstracts

Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.

Find out more